It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Macrophages participate in the pathogenesis of ankylosing spondylitis (AS) by producing inflammatory cytokines. Extracellular adenosine triphosphate (eATP), released during cell stress, acts through purinergic receptors (P2XR and P2YR) and induces inflammatory responses. We investigated the effect of 2ʹ(3ʹ)-O-(4-benzoyl benzoyl) ATP (BzATP) (a prototypic agonist of P2X7R) on the production of inflammatory cytokines in both monocyte-generated (M2-like) and M1 macrophages from patients and controls. Macrophages were differentiated from isolated periphery-monocytes (n = 14 in each group) by macrophage colony-stimulating factor (M-CSF). Using LPS and IFN-γ, macrophages were skewed toward M1 type and were treated with BzATP. Gene expression and protein release of IL-1β, IL-23, and TNF-α were evaluated by real-time PCR and ELISA methods respectively before and after treatment. BzATP significantly increased the protein release of TNF-α and the expression of TNFA and IL1B in monocyte-generated macrophages. Besides, BzATP treatment significantly upregulated IL1B expression, reduced TNFA and IL23A expression, and TNF-α release in M1 macrophages from both groups. Monocyte-generated and M1 macrophages from AS patients released higher TNF-α and expressed more IL1B in response to the same concentration of BzATP treatment respectively. Based on our results, AS macrophages were more sensitive to BzATP treatment and responded more intensively. Besides, the diverse effects of BzATP on monocyte-derived and M1 macrophages in our study may represent the differed inflammatory properties of these two groups of macrophages in response to eATP in the body.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Tehran, Department of Cell and Molecular Biology, School of Biology, College of Science, Tehran, Iran (GRID:grid.46072.37) (ISNI:0000 0004 0612 7950); Tehran University of Medical Sciences, Rheumatology Research Center, Shariati Hospital, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Tehran University of Medical Sciences, Inflammation Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
2 University of Tehran, Department of Cell and Molecular Biology, School of Biology, College of Science, Tehran, Iran (GRID:grid.46072.37) (ISNI:0000 0004 0612 7950)
3 Tehran University of Medical Sciences, Rheumatology Research Center, Shariati Hospital, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
4 Tehran University of Medical Sciences, Rheumatology Research Center, Shariati Hospital, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Tehran University of Medical Sciences, Inflammation Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)